Status:
WITHDRAWN
A Phase III Study of Re-Irradiation in Recurrent Glioblastoma
Lead Sponsor:
AHS Cancer Control Alberta
Conditions:
Recurrent Glioblastoma
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The investigators hope to improve overall median survival of patients with recurrent Glioblastoma by investigating continuous low-dose daily Temozolomide plus or minus five treatments of re-irradiatio...
Detailed Description
This is a stratified study for patients with recurrent intracranial glioblastoma or gliosarcoma previously treated with concurrent chemoradiation presenting radiographic progression or recurrence of t...
Eligibility Criteria
Inclusion
- histologically-proven intracranial glioblastoma or gliosarcoma previously treated with concurrent chemoradiation
- radiographic evidence of tumour progression or recurrence
- 18 years or older
- ECOG 0 - 2
- signed informed consent form
Exclusion
- tumour progression or recurrence within 3 months of initial concurrent chemoradiation
- 6 or more cycles of TMZ administered following chemoradiation at initial diagnosis
- more than one prior course of salvage chemo for recurrent disease
- prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for greater or equal to 3 years
- prior head or neck RT except for T1 glottic cancer
Key Trial Info
Start Date :
February 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2017
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01830101
Start Date
February 1 2014
End Date
November 1 2017
Last Update
March 16 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2